Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC Wainwright

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) had its price target hoisted by equities researchers at HC Wainwright from $66.00 to $72.00 in a research report issued on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's price target would indicate a potential upside of 59.22% from the company's previous close.

Other equities research analysts have also issued research reports about the stock. Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a research note on Thursday, February 27th. Citigroup upped their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $58.20.

Mirum Pharmaceuticals Stock Down 1.7 %

Shares of NASDAQ:MIRM traded down $0.77 during mid-day trading on Friday, hitting $45.22. 560,134 shares of the company traded hands, compared to its average volume of 541,360. The stock has a market cap of $2.22 billion, a P/E ratio of -22.39 and a beta of 0.96. The stock has a 50-day moving average price of $47.05 and a two-hundred day moving average price of $43.43. Mirum Pharmaceuticals has a 12-month low of $23.14 and a 12-month high of $54.23. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33.

Remove Ads

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to analysts' expectations of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. On average, equities research analysts forecast that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In related news, SVP Jolanda Howe sold 750 shares of the company's stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $42.82, for a total transaction of $32,115.00. Following the sale, the senior vice president now directly owns 2,926 shares in the company, valued at approximately $125,291.32. This represents a 20.40 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Peter Radovich sold 2,627 shares of the firm's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $126,673.94. Following the completion of the transaction, the chief operating officer now directly owns 26,961 shares of the company's stock, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,915 shares of company stock worth $1,897,920. 22.87% of the stock is owned by company insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Jones Financial Companies Lllp raised its stake in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Mirum Pharmaceuticals in the 4th quarter worth about $35,000. GF Fund Management CO. LTD. purchased a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after buying an additional 318 shares during the period. Finally, R Squared Ltd purchased a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth about $69,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.